What is CCEL's market cap?

$39.51M, based on the Nov 5 close of $4.90.

Does Cryo-Cell International pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CCEL is sold short?

7.1K shares, 0.2% of float, as of Oct 15, 2026.

What sector is CCEL in?

Healthcare, in the Health Services industry.

NYSE American · CCELHealthcareHealth Services

Cryo-Cell International Inc. (CCEL)

$4.90−3.35%

Close Nov 5, 2026 · split-adjusted

Nov 4, 2026$5.07▲ 16.89% in range

Nov 4, 2025Low $2.89 · High $5.35Nov 4, 2026

What changed · written from our data

As of Nov 5, 2026

Cryo-Cell International closed at $4.90 on Nov 5, down 3.35%, 8.4% below its 52-week closing high. Volume of 4.0K shares was 0.31× its 20-day average (below normal).

Split-adjusted performance: +25.3% over one month, +36.9% over six months.

In the quarter ended Aug 31, 2026, revenue was $7.82M, down 0.0% from a year earlier, with a net margin of 16.2%.

Short interest was 7.1K shares at the Oct 15 settlement, up 10.2% from the prior report (0.2% of float, 1.0 days to cover).

Market cap$39.5M8.1M shares

Revenue · quarter$7.8M0.0% YoY

Diluted EPS$0.16+77.8% YoY

P/E · TTM—P/S 1.3×

Net margin16.2%Gross 79.4%

Dividend yieldNone$0.15 last paid

52-week range2.89 – 5.35−8.4% from high

Volume4.0K0.31× 20-day avg

Volatility · 60d95.4%Annualised

Short % of float0.2%1.0 days to cover

Net cash-$4.9MCash $4.2M

Next earnings—Not scheduled

Split-adjusted performance

1W −5.5%1M +25.3%3M +36.1%6M +36.9%YTD +42.4%1Y —3Y −6.7%5Y −61.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Health Services

Percentile among 20 companies (100 = best)

6-month momentum74

Revenue growth24

Net margin89

Value (low P/E)—

Size26

Industry medians: 6-month return +10.3%, revenue growth +7.2%, net margin 3.0%, P/E 72.2×.

Short interest

Details →

Shares short7.1K+10.2% vs prior

Days to cover1.0Settled Oct 15

% of float0.2%

Short vol. 10d29.3%of daily volume

Closest peers by size in Health Services

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CCELCryo-Cell International	$4.90	−3.35%	+36.9%	0.0%	16.2%	—	$39.5M
EUDAEUDA Health Holdings Limited	$14.82	−7.38%	+10.3%	—	—	—	$44.4M	Compare
DCGODocGo	$0.2462	−5.51%	−61.2%	−8.7%	−21.5%	—	$24.4M	Compare
PARKPark Dental Partners	$20.30	−4.90%	+20.3%	—	2.0%	—	$96.5M	Compare
PIIIP3 Health Partners	$3.95	−3.66%	+10.3%	+8.6%	−0.6%	—	$15.5M	Compare
VMDViemed Healthcare	$8.91	−11.92%	−3.3%	+23.9%	3.5%	23.4	$339.2M	Compare
MGRXMangoceuticals	$0.1890	−8.74%	−44.4%	−37.9%	−5447.9%	—	$4.2M	Compare
BRTXBioRestorative Therapies, Inc. Common Stock (NV)	$1.54	+1.99%	−65.8%	−7.3%	−9298.3%	—	$2.1M	Compare
OMDAOmada Health	$18.53	−4.66%	+13.0%	+43.1%	6.0%	263.4	$1.13B	Compare

News about Cryo-Cell International

All news →

No recent articles focused on Cryo-Cell International. 1 articles mention it in passing.

Quick answers

What does Cryo-Cell International do?: Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells.
What is CCEL's market cap?: $39.51M, based on the Nov 5 close of $4.90.
Does Cryo-Cell International pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CCEL is sold short?: 7.1K shares, 0.2% of float, as of Oct 15, 2026.
What sector is CCEL in?: Healthcare, in the Health Services industry.

About Cryo-Cell International

Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.

HQ: Oldsmar, FL76 employeescryo-cell.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology